People have varying opinions about using CBD oil. One person might tell you that it is as effective as snake oil while another will swear it is a cure-all.
CBD oil has been proclaimed to be an effective treatment for anxiety, epilepsy, and psychosis. Today, it is added inside gummies, chewing gums, and even chocolates.
At the rate the CBD market today is growing, it is believed to be going to be almost £1 billion per annum in worth by 2025. That estimate includes only the CBD market in the UK.
There have been important concerns raised about the CBD market since the tests from the laboratory of Centre for Medicinal Cannabis (CMC) discovered that 62% of the products from the high street claiming to contain CBD did not contain it at all.
The deception did not end there. Apart from containing no significant traces of CBD, some of these products contained tetrahydrocannabinol (THC). THC is an illegal, intoxicating, and psychoactive compound that is responsible for the “high” people experience after taking cannabis. According to research, almost half of the tested products included either cannabinol or THC. Cannabinol is also a psychoactive chemical.
Although the amounts of THC and Cannabinol included in the tested products were most likely not enough to make people experience dizziness or confusion, they point to a large problem in the CBD market’s quality. How are these products getting into circulations? Where are the regulators of the CBD market, and why have they not seized these products?
Malik, the director of development in CMC, commented that most of the reason for these occurrences is the ignorance of the public about CBD. The chemistry of cannabis is still very much unknown.
Cannabis has more than 400 unique compounds. The prohibition on cannabis made it difficult for it to be subjected to thorough study and laboratory testing. It only became legal to be used for medicinal purposes last year. At the moment, there is a scarcity of chemists who are qualified cannabis experts, and these lead to many clumsy errors in the production of CBD products.
Sumnall, a professor of the use of substances at the university based in Liverpool, expressed his concern at the lack of manufacturing standards and quality control for CBD products despite the existence of agencies whose job it is to control it, namely the Food Standards Agency of the UK. He blamed the lack of control due the under-resourced conditions of the FSA and the departments that regulate medicines and health as well as the huge CBD market.
The CBD market has grown in worth by £300 million in a span of 3 years. Its retail demand is considerably higher than the pace of its regulation.
There are rules in UK law that help regulate CBD. To begin with, it is considered only when medically beneficial, and the doses given must be clinically approved. If THC is present in a product, a license must be acquired from Home Office before it is sold.
Unfortunately, these rules are not being adhered to. CBD has been hailed as a miraculous compound, according to Sumnal, and celebrities in the United States are endorsing it.
Bhatarah, the head of regulatory and compliance in CMC expressed the goals of CMC in setting up a standard of quality for CBD products and sharing their findings with FSA to increase the regulation in the CBD market.
Dragonfly CBD is a brand of cannabinoil that will be taking part in the review if products led by CMC. They are committed to prohibiting inaccuracy in product labeling and references.
Ultimately, no matter where the regulation of CBD products begins, any method of standardization will be of immense benefit to the customers of CBD.